This review of 31 randomised clinical trials involving almost 156,000 participants, of whom 84,461 were treated with an ARB, found no increased risk. The review analysed the data for new cancer cases, cancer-related death, breast cancer, lung cancer and prostate cancer. There was no increase in risk for any of these outcomes.
Action: Clinicians and patients can be reassured by this safety review. It is important to note that the overall evidence still places ARBs are still second line to angiotensin converting enzyme inhibitors (ACEIs).
|« NICE Guidance - May 2011||Drug Safety Update - June 2011 »|